NCT02146222 - VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

VEGFR/PDGFR dual kinase inhibitor X-82

Given PO

DRUG

docetaxel

Given IV

OTHER

fluorine F 18 fluorothymidine

Undergo FLT PET/CT

PROCEDURE

positron emission tomography/computed tomography

Undergo FLT PET/CT

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

University of Wisconsin-Carbone Cancer Center, Madison